Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Pegfilgrastim safely administered on the same day as dose-dense chemotherapy for patients with advanced-stage ovarian carcinoma.

Micha JP, Brown JV 3rd, Rettenmaier MA, Abaid LN, Mendivil AA, Lopez KL, Goldstein BH.

Clin Oncol (R Coll Radiol). 2013 Jun;25(6):390. doi: 10.1016/j.clon.2013.02.003. Epub 2013 Mar 13. No abstract available.

PMID:
23489872
2.

A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.

Tiersten AD, Sill MW, Knight D, Muggia F, Garcia AA, Swensen R, Warshal DP, Mannel RS, Fracasso PM.

Gynecol Oncol. 2010 Sep;118(3):303-7. doi: 10.1016/j.ygyno.2010.05.020. Epub 2010 Jun 14.

3.

Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.

Almenar D, Mayans J, Juan O, Bueno JM, Lopez JI, Frau A, Guinot M, Cerezuela P, Buscalla EG, Gasquet JA, Sanchez J.

Eur J Cancer Care (Engl). 2009 May;18(3):280-6. doi: 10.1111/j.1365-2354.2008.00959.x. Epub 2008 Dec 8.

4.

Overdose of pegfilgrastim: case report.

Riu G, Estefanell A, Nomdedeu M, Creus N.

Int J Clin Pharm. 2012 Oct;34(5):690-2. doi: 10.1007/s11096-012-9653-z. Epub 2012 Jul 21.

PMID:
22821554
5.

The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies.

Whitworth JM, Matthews KS, Shipman KA, Numnum TM, Kendrick JE, Kilgore LC, Straughn JM Jr.

Gynecol Oncol. 2009 Mar;112(3):601-4. doi: 10.1016/j.ygyno.2008.10.025. Epub 2008 Dec 24.

PMID:
19110303
6.

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.

Holmes FA, Jones SE, O'Shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, Dhami M, Budman DR, Hackett J, Brassard M, Yang BB, Liang BC.

Ann Oncol. 2002 Jun;13(6):903-9.

7.

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.

Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC.

J Clin Oncol. 2002 Feb 1;20(3):727-31.

PMID:
11821454
8.

The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study.

Di Leo A, Bajetta E, Nolè F, Biganzoli L, Ferrari L, Oriana S, Riboldi G, Bohm S, Spatti G, Raspagliesi F, et al.

Br J Cancer. 1994 May;69(5):961-6.

9.

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.

Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ; International Pegfilgrastim 749 Study Group.

Ann Oncol. 2003 Jan;14(1):29-35.

10.

Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.

de Wit R, Verweij J, Bontenbal M, Kruit WH, Seynaeve C, Schmitz PI, Stoter G.

J Natl Cancer Inst. 1996 Oct 2;88(19):1393-8.

11.

Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim.

Ishiguro H, Kitano T, Yoshibayashi H, Toi M, Ueno T, Yasuda H, Yanagihara K, Garbo CL, Fukushima M.

Ann Oncol. 2008 May;19(5):1019; author reply 1019-20. doi: 10.1093/annonc/mdn051. Epub 2008 Mar 5. No abstract available.

12.

Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.

Yoshida O, Kakehi Y, Arai Y, Tomoyoshi T, Okada Y, Matsuda T, Mikami O, Fukuyama T, Hida S, Okabe T.

Int J Urol. 1995 Nov;2(5):316-21. Erratum in: Int J Urol 1996 Jan;3(1):80.

13.
14.

The use of lenograstim (Granocyte) in chemotherapy for ovarian cancer.

Roongpisuthipong A, Suphanit I, Luamprapat A, Senapad S.

Asian Pac J Allergy Immunol. 1998 Mar;16(1):43-7.

15.

A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma.

Seymour AM, de Campos E, Thatcher N, De Greve J, Cunningham D, Howell A, Tueni E, Bron DG, Steward WP, Berdel WE, et al.

Eur J Cancer. 1995 Dec;31A(13-14):2157-63.

PMID:
8652235
17.

[High-dose epirubicin in combination with high-dose ifosfamide plus granulocyte colony stimulating factor in patients with advanced platin-pretreated ovarian cancer. Phase I-II study].

Küffer E, Fazeny B, Speiser P, Kurz C, Vavra N, Sevelda P, Dittrich C.

Gynakol Geburtshilfliche Rundsch. 1993;33 Suppl 1:296-8. German. No abstract available.

PMID:
7509676
18.

A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer.

Eguchi K, Etou H, Miyachi S, Morinari H, Nakada K, Noda K, Ohkuni Y, Watanabe K, Yamada Y, Ohe Y, et al.

Eur J Cancer. 1994;30A(2):188-94.

PMID:
7512356
19.

Different schedules of granulocyte growth factor support for patients with breast cancer receiving adjuvant dose-dense chemotherapy: a prospective nonrandomized study.

Hendler D, Rizel S, Yerushalmi R, Neiman V, Bonilla L, Braunstein R, Sulkes A, Stemmer SM.

Am J Clin Oncol. 2011 Dec;34(6):619-24. doi: 10.1097/COC.0b013e3181f94716.

PMID:
21217400
20.

A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.

Hecht JR, Pillai M, Gollard R, Heim W, Swan F, Patel R, Dreiling L, Mo M, Malik I.

Clin Colorectal Cancer. 2010 Apr;9(2):95-101. doi: 10.3816/CCC.2010.n.013.

PMID:
20378503
Items per page

Supplemental Content

Write to the Help Desk